Schatzlein, Andreas - University College London

个人简介

Andreas has a track record of medicines development and translational research in industry and academia. As a senior scientist at the biotech start-up IDEA in Munich, he was intimately involved in the scientific, clinical and commercial development of its transdermal delivery nanotechnology products. In 1996 he joined academia at the Cancer Research UK Beatson Laboratories at the University of Glasgow. He became leader of the Cancer Research UK’s Experimental Therapeutics and Gene Medicines Group. As Head of the Analytical Services Unit he was instrumental in the introduction of good clinical laboratory practice (GCLP) standards and responsible for the analysis of pharmacokinetics and pharmacodynamics readouts in a range of Translational Clinical Trials. Andreas research has been featured repeatedly in the media (TV, radio, print) and has been supported by the BBSRC, EPSRC, Wellcome Trust, Royal Society, Scottish Enterprise, Tenovus Scotland, CRUK, the Technology Strategy Board and FP7. Andreas is also co-founder and CEO of Nanomerics Ltd, a UCL spinout company developing pharmaceutical nanotechnology.

研究领域

Translational research in nanomedicine and cancer: My research is concerned with the translation of fundamental insights from the laboratory into medical therapies and focuses on the use of pharmaceutical nanotechnology, in particular in cancer Mechanisms – Molecules – Materials – Medicines: Based on our understanding of the mechanisms of biological barriers we are modifying molecules such as polymers to tune their supramolecular assembly and create nanosized materials which enable novel medicines Targeting Cancer and Cancer Genes: Achieving specificity is one of the key aims of our work in cancer. We investigate the mechanism of novel cancer specific compounds, we target conventional therapies using nano-medicines, and we delivery genetically targeted tumour therapies

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Chitosan amphiphile coating of peptide nanofibres reduces liver uptake and delivers the peptide to the brain on intravenous administration. Journal article ; 2015 ; J Control Release ; Netherlands links: IRIS ; UCL Discovery ; doi ; author's authors [click to collapse] : Lalatsa A,Schätzlein AG,Garrett NL,Moger J,Briggs M,Godfrey L,Iannitelli A,Freeman J,Uchegbu IF A nano-enabled cancer-specific ITCH RNAi chemotherapy booster for pancreatic cancer Journal article ; 2014 ; Nanomedicine: Nanotechnology, Biology and Medicine links: IRIS ; UCL Discovery authors [click to collapse] : de la Fuente M,Jones MC,Santander-Ortega MJ,Mirenska A,Marimuthu M,Uchegbu I,Schatzlein AG Physical characterisation and long-term stability studies on quaternary ammonium palmitoyl glycol chitosan (GCPQ) - A new drug delivery polymer Journal article ; 2014 ; Journal of Pharmaceutical Sciences links: IRIS ; UCL Discovery ; doi authors [click to collapse] : Chooi KW,Simão Carlos MI,Soundararajan R,Gaisford S,Arifin N,Schätzlein AG,Uchegbu IF Polymers in Drug Delivery Book ; 2006 ; CRC Press links: IRIS ; UCL Discovery authors : Uchegbu IF,Schatzlein AG The Oral and Intranasal Delivery of Propofol Using Chitosan AmphiphileNanoparticles Journal article ; 2014 ; Pharmaceutical Nanotechnology links: IRIS ; UCL Discovery ; publisher authors [click to collapse] : Uchegbu IF,Jones MC,Corrente F,Godley L,Laghezza D,Cafara M,Holm P,Schätzlein AG Optimisation of synthetic vector systems for cancer gene therapy - the role of the excess of cationic dendrimer under physiological conditions. Journal article ; 2014 ; Curr Top Med Chem ; Netherlands links: IRIS ; UCL Discovery ; author's authors [click to collapse] : Santander-Ortega MJ,de la Fuente M,Lozano MV,Tsui ML,Bolton K,Uchegbu IF,Schätzlein AG Lomustine nanoparticles are effective brain cancer treatments. Conference ; 2013 ; CANCER RESEARCH links: IRIS ; UCL Discovery ; doi ; author's authors [click to collapse] : Fisusi FA,Alzharani A,Summers I,Morger J,Okubanjo O,Chooi KW,Schaetzlein AG,Uchegbu IF GC-t8-linked pyrrolobenzodiazepine (PBD)-biaryl conjugates with femptomolar in vitro cytotoxicity and in vivo antitumour activity in mouse models of pancreatic and breast cancer. Conference ; 2013 ; CANCER RESEARCH links: IRIS ; UCL Discovery ; doi ; author's authors [click to collapse] : Rahman KM,Jackson PJM,James CH,Basu BP,Hartley JA,de la Fuente M,Schatzlein A,Robson M,Pedley B,Pepper C,Fox KR,Howard PW,Thurston DE Chitosan amphiphiles provide new drug delivery opportunities Journal article ; 2014 ; Polymer International links: IRIS ; UCL Discovery ; doi authors [click to collapse] : Uchegbu IF,Carlos M,McKay C,Hou X,Schätzlein AG Strategies to deliver peptide drugs to the brain. Journal article ; 2014 ; Mol Pharm ; United States links: IRIS ; UCL Discovery ; doi ; author's authors [click to collapse] : Lalatsa A,Schatzlein AG,Uchegbu IF Amphotericin B Formulations – The Possibility of Generic Competition Journal article ; 2013 ; Pharmaceutical Nanotechnology links: IRIS ; UCL Discovery ; publisher authors [click to collapse] : Serrano DR,Ballestros MP,Schatzlein AG,Torrado JJ,Uchegbu IF Biological Barriers: Transdermal, Oral, Mucosal, Blood Brain Barrier, and the Blood Eye Barrier Chapter ; Fundamentals of Pharmaceutical Nanoscience ; Springer links: IRIS ; UCL Discovery ; publisher authors : Marimuthu P,Schatzlein AG Fundamentals of Pharmaceutical Nanoscience Book ; 2013 links: IRIS ; UCL Discovery ; publisher authors : Schatzlein AG Inhibition of the hypoxia-inducible factor pathway by a G-quadruplex binding small molecule Journal article ; 2013 ; SCIENTIFIC REPORTS links: IRIS ; UCL Discovery ; doi ; author's authors [click to collapse] : Welsh SJ,Dale AG,Lombardo CM,Valentine H,de la Fuente M,Schatzlein A,Neidle S Rapid and sensitive liquid chromatographic method for determination of etoposide in plasma and biological samples Journal article ; 2013 ; Journal of Liquid Chromatography and Related Technologies links: IRIS ; UCL Discovery ; doi authors [click to collapse] : Raza A,Aman A,Bashir S,Ahmad B,Irfan J,Mehta JD,Gill HS,Khan A,Alam M,Schätzlein AG Functional characterization of heat shock protein 90 targeted compounds. Journal article ; 2013 ; Anal Biochem ; United States links: IRIS ; UCL Discovery ; doi ; author's authors [click to collapse] : Cruz IN,Zhang Y,de la Fuente M,Schatzlein A,Yang M GC-targeted C8-linked pyrrolobenzodiazepine-biaryl conjugates with femtomolar in vitro cytotoxicity and in vivo antitumor activity in mouse models. Journal article ; 2013 ; J Med Chem ; United States links: IRIS ; UCL Discovery ; doi ; author's authors [click to collapse] : Rahman KM,Jackson PJ,James CH,Basu BP,Hartley JA,de la Fuente M,Schatzlein A,Robson M,Pedley RB,Pepper C,Fox KR,Howard PW,Thurston DE Dextran-pegylated microparticles for enhanced cellular uptake of hydrophobic drugs. Journal article ; 2013 ; Eur J Pharm Biopharm ; Netherlands links: IRIS ; UCL Discovery ; doi ; author's authors [click to collapse] : Cassano R,Ferrarelli T,Schätzlein AG,Uchegbu IF,Trombino S Fast gelation of self-assembling peptide nanofibres triggered by electromagnetic radiation heating Conference ; 2011 ; Technical Proceedings of the 2011 NSTI Nanotechnology Conference and Expo, NSTI-Nanotech 2011. ; Boston - MA, US links: IRIS ; UCL Discovery authors [click to collapse] : Mazza M,Schatzlein A,Uchegbu I,Gaisford D,McCarthy D Nanofiber-based delivery of therapeutic peptides to the brain. Journal article ; 2013 ; ACS Nano ; United States links: IRIS ; UCL Discovery ; doi ; author's authors [click to collapse] : Mazza M,Notman R,Anwar J,Rodger A,Hicks M,Parkinson G,McCarthy D,Daviter T,Moger J,Garrett N,Mead T,Briggs M,Schätzlein AG,Uchegbu IF Bioactive Polymers Patent ; 2008 links: IRIS ; UCL Discovery authors [click to collapse] : Schatzlein AG,Uchegbu IF,Dufes C Oral delivery of hydrophilic drugs to the brain Patent ; 2011 ; EU links: IRIS ; UCL Discovery authors [click to collapse] : Schatzlein AG,Lalatsaa A,Uchegbu IF Delivery of hydrophilic drugs Patent ; 2010 links: IRIS ; UCL Discovery authors [click to collapse] : Schatzlein AG,Lalatsa A,Uchegbu IF Delivery of hydrophilic drugs Patent ; 2012 ; US links: IRIS ; UCL Discovery authors : Schatzlein AG Solubilising polysaccharides substituted with dydrophilic and hydrophobic groups Patent ; 2010 links: IRIS ; UCL Discovery authors [click to collapse] : Schatzlein AG,Uchegbu IF,Stewart A,Wilson C